Rituximab — CAS 174722-31-7

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is widely used in the treatment of B-cell non-Hodgkin lymphoma, chronic lymphocytic leukaemia, and several autoimmune conditions. Mediocon Inc manufactures GMP-compliant Rituximab at its Aurangabad facility.

• Non-Hodgkin lymphoma (NHL) treatment
• Chronic lymphocytic leukaemia (CLL)
• Rheumatoid arthritis (second-line)
• Granulomatosis with polyangiitis
• Pemphigus vulgaris

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / EP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support